GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

A series of stories that looks at the breakthroughs, setbacks, and overall status of vaccines and cures for hard-to-treat ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.

Inequalities in childhood vaccination are widening in England, with uptake rates of five key vaccines consistently lower in young children living in areas of higher deprivation from 2019 to 2023, ...

The arrest in the slaying of UnitedHealthcare CEO Brian Thompson was the first step to putting his alleged killer behind bars ...

CHELMSFORD, MA / ACCESSWIRE / December 10, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), the 101-year-old Massachusetts-based global customer experience company, today announced it's collaborating with Reddy ...

A North East accountancy firm has achieved a prestigious accolade for its outstanding commitment to employee training and ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...